Home | Log in or Sign Up for full access | Tracked Organizations | Recent Tracked Activities

Recent Activities

Activities between Nov. 15, 2024, 8:08 p.m. and Nov. 22, 2024, 8:08 p.m. in: Sichuan Sheng (China).

Click on a document link to see the original source document. Click on the name of an organization to see more organization linkages and timelines.


C Ray Therapeutics Completes Over $100 Million Series A+ Financing, Jointly Led by SCGC and TaiLong Capital

Document Date: Nov. 18, 2024, 2 p.m. / Source: PR Newswire
Activity Class: CorporateFinanceActivity / Type: Investment / Region: People’s Republic of China
Investor: Target: Document Extract: CHENGDU, China, Nov. 18, 2024 /PRNewswire/ - In November 2024, C Ray Therapeutics (Chengdu) Co., Ltd. (hereinafter referred to as "C Ray") , an innovative enterprise in the field of radiopharmaceuticals, announced the completion of its Series A+ financing round exceeding $ 100 million.
Document Source: https://www.prnewswire.com/news-releases/c-ray-therapeutics-completes-over-100-million-series-a-financing-jointly-led-by-scgc-and-tailong-capital-302308428.html (archive.org page / archive.org listing)


DP Technology and Lepu Biopharma Announce Milestone Collaboration: Leveraging Advanced Computational Methods to Accelerate ADC Drug Innovation

Document Date: Nov. 21, 2024, 5:01 a.m. / Source: PR Newswire
Activity Class: PartnershipActivity / Region: People’s Republic of China
Partnership: Document Extract: DP Technology and Lepu Biopharma Announce Milestone Collaboration: Leveraging Advanced Computational Methods to Accelerate ADC Drug Innovation. This partnership has effectively integrated DP's ADC Linker-Payload design platform with Lepu's ADC technology development platform, capitalizing on their respective strengths. The overall optimization of the ADC drug has been achieved in a relatively short time. BEIJING, Nov. 20, 2024 /PRNewswire/ - Lepu Biopharma Co., Ltd. (Lepu Biopharma) and Beijing DP Tech Co., Ltd. (DP Technology) have recently announced a significant milestone in their Antibody-Drug Conjugate (ADC) drug collaboration. This partnership has effectively integrated DP's ADC Linker-Payload design platform with Lepu's ADC technology development platform, capitalizing on their respective strengths.
Document Source: https://www.prnewswire.com/news-releases/dp-technology-and-lepu-biopharma-announce-milestone-collaboration-leveraging-advanced-computational-methods-to-accelerate-adc-drug-innovation-302312430.html (archive.org page / archive.org listing)


DP Technology and Lepu Biopharma Announce Milestone Collaboration: Leveraging Advanced Computational Methods to Accelerate ADC Drug Innovation

Document Date: Nov. 21, 2024, 5:01 a.m. / Source: PR Newswire
Activity Class: PartnershipActivity
Partnership: Document Extract: The overall optimization of the ADC drug has been achieved in a relatively short time. BEIJING, Nov. 20, 2024 /PRNewswire/ - Lepu Biopharma Co., Ltd. (Lepu Biopharma) and Beijing DP Tech Co., Ltd. (DP Technology) have recently announced a significant milestone in their Antibody-Drug Conjugate (ADC) drug collaboration. This partnership has effectively integrated DP's ADC Linker-Payload design platform with Lepu's ADC technology development platform, capitalizing on their respective strengths. The overall optimization of the ADC drug has been achieved in a relatively short time. This project has reached an important milestone, further validating the approach of accelerating ADC innovative drug development through computational design.
Document Source: https://www.prnewswire.com/news-releases/dp-technology-and-lepu-biopharma-announce-milestone-collaboration-leveraging-advanced-computational-methods-to-accelerate-adc-drug-innovation-302312430.html (archive.org page / archive.org listing)


DP Technology and Lepu Biopharma Announce Milestone Collaboration: Leveraging Advanced Computational Methods to Accelerate ADC Drug Innovation

Document Date: Nov. 21, 2024, 5:01 a.m. / Source: PR Newswire
Activity Class: PartnershipActivity
Partnership: Document Extract: Furthermore, "AI + first principles" based computational methods are employed to predict linker cleavage sites and ensure the correct payload release, achieving outstanding cell-killing and bystander effects. Additionally, the designed antibody-drug conjugates (ADCs) maintain excellent hydrophilicity and plasma stability. Leveraging Lepu's mature and complete ADC development system, candidates developed by the new ADC platform have demonstrated significant efficacy in CDX models targeting multiple targets. This project has been successfully validated in animal models and is currently advancing the candidate ADC to the clinical stage. Lei Fang, Ph.D., Vice President of Lepu Biopharma and CEO of CtM Bio Co., Ltd., expressed high appreciation for this cooperation: "Introducing advanced computational methods to solve scientific problems and jointly pioneering breakthrough explorations is our goal in the ADC project collaboration.
Document Source: https://www.prnewswire.com/news-releases/dp-technology-and-lepu-biopharma-announce-milestone-collaboration-leveraging-advanced-computational-methods-to-accelerate-adc-drug-innovation-302312430.html (archive.org page / archive.org listing)


DP Technology and Lepu Biopharma Announce Milestone Collaboration: Leveraging Advanced Computational Methods to Accelerate ADC Drug Innovation

Document Date: Nov. 21, 2024, 5:01 a.m. / Source: PR Newswire
Activity Class: PartnershipActivity
Partnership: Document Extract: This partnership has effectively integrated DP's ADC Linker-Payload design platform with Lepu's ADC technology development platform, capitalizing on their respective strengths. The overall optimization of the ADC drug has been achieved in a relatively short time. BEIJING, Nov. 20, 2024 /PRNewswire/ - Lepu Biopharma Co., Ltd. (Lepu Biopharma) and Beijing DP Tech Co., Ltd. (DP Technology) have recently announced a significant milestone in their Antibody-Drug Conjugate (ADC) drug collaboration. This partnership has effectively integrated DP's ADC Linker-Payload design platform with Lepu's ADC technology development platform, capitalizing on their respective strengths. The overall optimization of the ADC drug has been achieved in a relatively short time.
Document Source: https://www.prnewswire.com/news-releases/dp-technology-and-lepu-biopharma-announce-milestone-collaboration-leveraging-advanced-computational-methods-to-accelerate-adc-drug-innovation-302312430.html (archive.org page / archive.org listing)

Archive.org page links will work if the page has already been archived by archive.org, but we can't guarantee which pages archive.org has archived so far.

Treat sameAsNameOnly relationship as same? Yes (Turn Off)

Site Stats | About (includes privacy and cookie notices)
(c) by 1145, 2023-2024. Data licensed under the Open Database License. Please send an email if you need a non-share-alike license and/or you need API access.